Department of Radiation Oncology, New York University Langone Health and Perlmutter Cancer Center, New York, New York.
Tufts University Graduate School of Biomedical Sciences, Boston, Massachusetts.
Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):468-478. doi: 10.1016/j.ijrobp.2023.04.006. Epub 2023 Apr 14.
Acute radiation dermatitis (ARD) is common after radiation therapy for breast cancer, with data indicating that ARD may disproportionately affect Black or African American (AA) patients. We evaluated the effect of skin of color (SOC) on physician-reported ARD in patients treated with radiation therapy.
We identified patients treated with whole breast or chest wall ± regional nodal irradiation or high tangents using 50 Gy in 25 fractions from 2015 to 2018. Baseline skin pigmentation was assessed using the Fitzpatrick scale (I = light/pale white to VI = black/very dark brown) with SOC defined as Fitzpatrick scale IV to VI. We evaluated associations among SOC, physician-reported ARD, late hyperpigmentation, and use of oral and topical treatments for RD using multivariable models.
A total of 325 patients met eligibility, of which 40% had SOC (n = 129). On multivariable analysis, Black/AA race and chest wall irradiation had a lower odds of physician-reported grade 2 or 3 ARD (odds ratio [OR], 0.110; 95% confidence interval [CI], 0.030-0.397; P = .001; OR, 0.377; 95% CI, 0.161-0.883; P = .025), whereas skin bolus (OR, 8.029; 95% CI, 3.655-17.635; P = 0) and planning target volume D0.03cc (OR, 1.001; 95% CI, 1.000-1.001; P = .028) were associated with increased odds. On multivariable analysis, SOC (OR, 3.658; 95% CI, 1.236-10.830; P = .019) and skin bolus (OR, 26.786; 95% CI, 4.235-169.432; P = 0) were associated with increased odds of physician-reported late grade 2 or 3 hyperpigmentation. There was less frequent use of topical steroids to treat ARD and more frequent use of oral analgesics in SOC versus non-SOC patients (43% vs 63%, P < .001; 50% vs 38%, P = .05, respectively).
Black/AA patients exhibited lower odds of physician-reported ARD. However, we found higher odds of late hyperpigmentation in SOC patients, independent of self-reported race. These findings suggest that ARD may be underdiagnosed in SOC when using the physician-rated scale despite this late evidence of radiation-induced skin toxicity.
急性放射性皮炎(ARD)是乳腺癌放射治疗后的常见并发症,有数据表明 ARD 可能不成比例地影响黑人和非裔美国人(AA)患者。我们评估了肤色(SOC)对接受放射治疗的患者中医生报告的 ARD 的影响。
我们从 2015 年至 2018 年期间,使用 50Gy/25 次的剂量,识别了接受全乳或胸壁±区域淋巴结照射或高切线照射的患者。使用 Fitzpatrick 量表(I=浅色/苍白至 VI=黑色/非常深棕色)评估基线皮肤色素沉着,SOC 定义为 Fitzpatrick 量表 IV 至 VI。我们使用多变量模型评估 SOC、医生报告的 ARD、迟发性色素沉着过度以及 RD 口服和局部治疗的使用之间的关联。
共有 325 名符合入选标准的患者,其中 40%(n=129)为 SOC。多变量分析显示,黑人和 AA 种族和胸壁照射的医生报告的 2 级或 3 级 ARD 的可能性较低(比值比[OR],0.110;95%置信区间[CI],0.030-0.397;P=0.001;OR,0.377;95%CI,0.161-0.883;P=0.025),而皮肤缓冲物(OR,8.029;95%CI,3.655-17.635;P=0)和计划靶区 D0.03cc(OR,1.001;95%CI,1.000-1.001;P=0.028)与增加的可能性相关。多变量分析显示,SOC(OR,3.658;95%CI,1.236-10.830;P=0.019)和皮肤缓冲物(OR,26.786;95%CI,4.235-169.432;P=0)与医生报告的迟发性 2 级或 3 级色素沉着过度的可能性增加相关。SOC 患者接受 ARD 治疗的局部皮质类固醇治疗频率较低,口服止痛药治疗频率较高(43% vs 63%,P<0.001;50% vs 38%,P=0.05)。
黑人和 AA 患者的医生报告 ARD 可能性较低。然而,我们发现 SOC 患者迟发性色素沉着过度的可能性更高,这与自我报告的种族无关。这些发现表明,尽管存在这种迟发性放射诱导皮肤毒性的证据,但使用医生评分量表时,SOC 患者的 ARD 可能被低估。